Inozyme Pharma Inc (NASDAQ:INZY)’s traded shares stood at 0.59 million during the last session, with the company’s beta value hitting 1.54. At the close of trading, the stock’s price was $4.51, to imply a decrease of -1.53% or -$0.07 in intraday trading. The INZY share’s 52-week high remains $7.80, putting it -72.95% down since that peak but still an impressive 40.35% since price per share fell to its 52-week low of $2.69. The company has a valuation of $278.58M, with an average of 657.43K shares over the past 3 months.
Inozyme Pharma Inc (NASDAQ:INZY) trade information
After registering a -1.53% downside in the last session, Inozyme Pharma Inc (INZY) has traded red over the past five days. The stock hit a weekly high of 5.11, dropping -1.53% in its intraday price action. The 5-day price performance for the stock is -12.26%, and -23.69% over 30 days. With these gigs, the year-to-date price performance is 5.87%.
Inozyme Pharma Inc (INZY) estimates and forecasts
Looking at statistics comparing Inozyme Pharma Inc share performance against respective industry, we note that the company has underperformed competitors. Inozyme Pharma Inc (INZY) shares are 46.91% up over the last 6 months, with its year-to-date growth rate lower than industry average at -6.57% against 13.30%. Revenue is forecast to grow 10.00% this quarter before falling -2.90% for the next one.
Revenue forecast for the current quarter as set by 6 analysts is -$. Meanwhile, for the quarter ending Jun 2024, a total of 6 analyst(s) estimate revenue growth to -$.Earnings reports from the last fiscal year show that sales brought in -$ and -$ respectively in the corresponding quarters.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -35.73% for the past 5-year period. While 2024 is set for a -7.78% return in earnings, projections for the next 5 years are at 13.10% annually.
INZY Dividends
Inozyme Pharma Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Inozyme Pharma Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
